Solid Tumor, Unspecified, Adult Clinical Trial
Official title:
Phase 1, Open Label, Dose Escalation and Expansion Study of RLY-1971, a Highly Potent and Selective SHP2 Inhibitor, in Subjects With Advanced or Metastatic Solid Tumors
Verified date | January 2023 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a multi-center, open-label, dose escalation and expansion study of RLY-1971 in subjects with advanced or metastatic solid tumors.
Status | Completed |
Enrollment | 56 |
Est. completion date | November 22, 2022 |
Est. primary completion date | November 22, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Subject is willing and able to provide written informed consent for the study prior to the performance of any study-specific procedures Subject is a male or female subject =18 years of age at the time of consent Subject must have an ECOG PS = 1 Subject must have histologically or cytologically confirmed advanced or metastatic solid tumor Subjects who are refractory to FDA-approved, standard therapy or for which standard or curative therapy does not exist or is not considered sufficient or appropriate by the patient or Investigator Subject must have radiographically measurable or evaluable disease Subject must have recovered from the reversible effects of prior anti-neoplastic therapy, except for alopecia and = grade 2 neuropathy. Subject has adequate end organ function Subject is willing to comply with all protocol-required visits, assessments, and procedures Male and female subjects of child-bearing potential are willing to use medically acceptable methods of birth control from the screening visit through 30 days after the last dose of study medication Exclusion Criteria: Subjects with documented history of tumor mutations that may not be amenable to treatment with RLY-1971, including: KRAS mutations: G12D, G12V, G13X, and Q61X BRAF V600E mutation MEK mutations Subjects with prior antineoplastic therapy within 3 weeks of Study Day 1, or 5 half-lives, whichever is shorter Subjects with prior palliative radiotherapy within 1 week of Study Day 1 Subjects who have had major surgery or trauma, or incomplete recovery from surgery or trauma, within 4 weeks of Study Day 1 Subjects with known central nervous system (CNS) metastases or primary CNS tumor that is associated with progressive neurologic symptoms or requires increasing doses of corticosteroids to control the CNS disease. If patient requires corticosteroids for management of CNS disease, the dose must have been stable for the 2 weeks preceding C1D1, or subject has new lesions appearing on follow up brain MRI that require CNS-directed intervention. Subjects with a history or evidence of ophthalmic disease Subjects with a history or evidence of significant cardiac dysfunction Subjects with a history or evidence of significant gastrointestinal disease Subjects with other serious concurrent medical conditions Subject is pregnant, as documented by a serum beta human chorionic gonadotropin (ß-hCG) pregnancy test consistent with pregnancy obtained within 7 days before the first dose of study treatment |
Country | Name | City | State |
---|---|---|---|
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Massachusetts General Hospital Cancer Center | Boston | Massachusetts |
United States | Florida Cancer Specialist-Lake Mary | Lake Mary | Florida |
United States | Tennessee Oncology; Sarah Cannon Research Institute | Nashville | Tennessee |
United States | Florida Cancer Specialists - Sarasota | Sarasota | Florida |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in phospho-ERK levels | Blood will be collected at pre-dose at baseline on Cycle 1, Day 1 (C1D1) and at 3 time points (pre-dose, 2 hours post-dose, and 4 hours post-dose) on Cycle 1, Day 15 (C1D15) to assess the extent of target engagement | At the beginning of Cycle 1 Day 1 post and predose (Cycle = 21 days) | |
Other | Tumor mutations by sequencing circulating tumor DNA (ctDNA) | Blood will be collected at screening and at End of Treatment on all patients | At the beginning of Cycle 1 Day 1 | |
Other | Duration of Response (DOR) | DOR is defined as the time from the participant's initial objective response (CR or PR) to RLY-1971, to disease progression or death due to any cause, whichever occurs first | Through study completion (an average of one year) | |
Other | Progression-free Survival (PFS) | PFS is defined as the time from the start of study treatment to the first documented disease progression per RECIST v1.1, or death due to any cause, whichever occurs first | Through study completion (an average of one year) | |
Primary | Maximum Tolerated Dose (MTD) | MTD is defined as a dose level immediately below that at which =2 of 6 subjects experience a DLT during the first cycle. | Escalation Phase - 18 month Enrollment | |
Primary | Recommended Phase 2 Dose (RP2D) | RP2D may be the same dose level or lower than the determined MTD. | Escalation Phase - 18 month Enrollment | |
Secondary | Plasma concentration levels of RLY-1971 | Blood samples may be taken at pre-dose, 0.5, 1, 2, 4, 6, and 8hrs on Cycle 1 Day 1 and 15, 24 hrs post dose on Cycle 1 Day 2, and pre-dose on Cycle 2 Day 1 | At the beginning of Cycle 1 & Cycle 2 (Each Cycle is 21 days) | |
Secondary | Objective Response Rate (ORR) | Evaluation by RECIST 1.1; ORR is defined as the proportion of subjects in the response evaluable population who achieve the best overall response (BOR) of CR or PR | Through study completion (an average of one year) | |
Secondary | Disease Control Rate (DCR) | DCR is defined as the percentage of response evaluable subjects who achieve a BOR of CR, PR or SD for at least 3 months | Through study completion (an average of one year) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03628677 -
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05723640 -
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection
|
Phase 1 | |
Completed |
NCT04976803 -
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
|
||
Recruiting |
NCT04932525 -
Gustave Roussy Cancer Profiling
|
Phase 1 | |
Recruiting |
NCT04643418 -
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04443088 -
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04942717 -
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
|
||
Recruiting |
NCT04169321 -
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
|
Phase 1 | |
Recruiting |
NCT05695638 -
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
|
||
Completed |
NCT03318445 -
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
|
Phase 1 | |
Recruiting |
NCT04537936 -
Psychotherapy Intervention for Latinos With Adv Cancer
|
N/A | |
Active, not recruiting |
NCT04577963 -
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06136065 -
68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors
|
Phase 2 | |
Recruiting |
NCT04015609 -
Psychotherapy Intervention for Latinos With Advanced Cancer
|
N/A | |
Available |
NCT04100694 -
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
|